Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,978 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators. Makker V, et al. Among authors: kim ym. N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045221 Clinical Trial.
Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer.
Kim YS, Shin SS, Nam JH, Kim YT, Kim YM, Kim JH, Choi EK. Kim YS, et al. Among authors: kim ym, kim yt, kim jh. Gynecol Oncol. 2008 Jan;108(1):195-200. doi: 10.1016/j.ygyno.2007.09.022. Epub 2007 Oct 25. Gynecol Oncol. 2008. PMID: 17963825 Clinical Trial.
Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB2 and IIA2 cervical cancer.
Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Kim YS, Kim HJ, Lee JW, Kim BG, Bae DS, Huh SJ, Nam JH. Park JY, et al. Among authors: kim hj, kim ym, kim dy, kim bg, kim ys, kim yt, kim jh. J Gynecol Oncol. 2012 Oct;23(4):226-34. doi: 10.3802/jgo.2012.23.4.226. Epub 2012 Sep 19. J Gynecol Oncol. 2012. PMID: 23094125 Free PMC article.
Korean epithelial ovarian cancer study (Ko-EVE): protocols and interim report.
Ma SH, Kim BG, Choi JY, Kim TJ, Kim YM, Kim JW, Kang S, Kang D, Yoo KY, Park SK. Ma SH, et al. Among authors: kim ym, kim bg, kim tj, kim jw. Asian Pac J Cancer Prev. 2012;13(8):3731-40. doi: 10.7314/apjcp.2012.13.8.3731. Asian Pac J Cancer Prev. 2012. PMID: 23098463 Free article.
Hormonal therapy for women with stage IA endometrial cancer of all grades.
Park JY, Kim DY, Kim TJ, Kim JW, Kim JH, Kim YM, Kim YT, Bae DS, Nam JH. Park JY, et al. Among authors: kim ym, kim dy, kim tj, kim yt, kim jw, kim jh. Obstet Gynecol. 2013 Jul;122(1):7-14. doi: 10.1097/AOG.0b013e3182964ce3. Obstet Gynecol. 2013. PMID: 23743459
Cost-utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model.
Lee HY, Yang BM, Hong JM, Lee TJ, Kim BG, Kim JW, Kim YT, Kim YM, Kang S. Lee HY, et al. Among authors: kim ym, kim bg, kim yt, kim jw. Clinicoecon Outcomes Res. 2013 Jul 3;5:297-307. doi: 10.2147/CEOR.S42170. Print 2013. Clinicoecon Outcomes Res. 2013. PMID: 23869171 Free PMC article.
An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021).
Lee SW, Kim YM, Cho CH, Kim YT, Kim SM, Hur SY, Kim JH, Kim BG, Kim SC, Ryu HS, Kang SB. Lee SW, et al. Among authors: kim sc, kim ym, kim bg, kim sm, kim yt, kim jh. Cancer Res Treat. 2018 Jan;50(1):195-203. doi: 10.4143/crt.2016.376. Epub 2017 Mar 21. Cancer Res Treat. 2018. PMID: 28324920 Free PMC article. Clinical Trial.
3,978 results